Contrasting roles of dietary selenium and selenoproteins in chemically induced hepatocarcinogenesis

Carcinogenesis

Volumn 34, Issue 5, 2013, Pages 1089-1095

  Kasaikina, Marina V ^a   Turanov, Anton A ^a   Avanesov, Andrei ^a   Schweizer, Ulrich ^b   Seeher, Sandra ^b   Bronson, Roderick T ^c   Novoselov, Sergey N ^d   Carlson, Bradley A ^e   Hatfield, Dolph L ^e   Gladyshev, Vadim N ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONATE DEHYDRATASE III; CARBONYL REDUCTASE; CARBONYL REDUCTASE 3; CATALASE; CYSTEINE TRANSFER RNA; DIETHYLNITROSAMINE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTATHIONE REDUCTASE; SELENOCYSTEINE; SELENOPROTEIN; SODIUM SELENITE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PREVENTION; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; DIETARY INTAKE; DNA MODIFICATION; EXPERIMENTAL MODEL; FEMALE; GENE EXPRESSION; GENOTYPE; LIVER CARCINOGENESIS; MALE; MOUSE; NEUROLOGIC DISEASE; NEWBORN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RNA GENE; SELENIUM DEFICIENCY; SURVIVAL; WILD TYPE;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DIET; FEMALE; GENOTYPE; LIVER NEOPLASMS; MICE; MICE, INBRED C57BL; PHENOTYPE; RNA, TRANSFER, AMINO ACID-SPECIFIC; SELENIUM; SELENOPROTEINS;

EID: 84877126368     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt011     Document Type: Article

References (26)

1. Brigelius-Flohé, R. (2008) Selenium compounds and selenoproteins in cancer. Chem. Biodivers., 5, 389-395.
2. Zhuo, P. et al. (2009) Molecular mechanisms by which selenoproteins affect cancer risk and progression. Biochim. Biophys. Acta, 1790, 1546-1554.
3. Hatfield, D.L. et al. (2009) Selenoproteins that function in cancer prevention and promotion. Biochim. Biophys. Acta, 1790, 1541-1545.
4. Duffield-Lillico, A.J. et al. (2003) Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int., 91, 608-612.
5. Duffield-Lillico, A.J. et al. (2002) Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol. Biomarkers Prev., 11, 630-639.
6. Xia, Y. et al. (2005) Effectiveness of selenium supplements in a low-selenium area of China. Am. J. Clin. Nutr., 81, 829-834.
7. Rayman, M.P. (2009) Selenoproteins and human health: insights from epidemiological data. Biochim. Biophys. Acta, 1790, 1533-1540.
8. Hatfield, D.L., Gladyshev, V.N. et al. (2009) The Outcome of Selenium and Vitamin E Cancer Prevention Trial (SELECT) reveals the need for better understanding of selenium biology. Mol. Interv., 9, 18-21.
9. Yoo, M.H. et al. (2006) Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. J. Biol. Chem., 281, 13005-13008.
10. Yoo, M.H. et al. (2007) Targeting thioredoxin reductase 1 reduction in cancer cells inhibits self-sufficient growth and DNA replication. PLoS ONE, 2, e1112.
11. Irons, R. et al. (2010) Deficiency in the 15-kDa selenoprotein inhibits tumorigenicity and metastasis of colon cancer cells. Cancer Prev. Res. (Phila)., 3, 630-639.
12. Carlson, B.A. et al. (2012) Thioredoxin reductase 1 protects against chemically induced hepatocarcinogenesis via control of cellular redox homeostasis. Carcinogenesis, 33, 1806-1813.
13. Driscoll, D.M. et al. (2003) Mechanism and regulation of selenoprotein synthesis. Annu. Rev. Nutr., 23, 17-40.
14. Carlson, B.A. et al. (2009) The selenocysteine tRNA STAF-binding region is essential for adequate selenocysteine tRNA status, selenoprotein expression and early age survival of mice. Biochem. J., 418, 61-71.
15. Novoselov, S.V. et al. (2005) Selenoprotein deficiency and high levels of selenium compounds can effectively inhibit hepatocarcinogenesis in transgenic mice. Oncogene, 24, 8003-8011.
16. Hornberger, T.A. et al. (2003) Selenoprotein-deficient transgenic mice exhibit enhanced exercise-induced muscle growth. J. Nutr., 133, 3091-3097.
17. Wirth, E.K. et al. (2010) Neuronal selenoprotein expression is required for interneuron development and prevents seizures and neurodegeneration. FASEB J., 24, 844-852.
18. Moustafa, M.E. et al. (2001) Selective inhibition of selenocysteine tRNA maturation and selenoprotein synthesis in transgenic mice expressing isopentenyladenosine-deficient selenocysteine tRNA. Mol. Cell. Biol., 21, 3840-3852.
19. Seiler, A. et al. (2008) Glutathione peroxidase 4 senses and translates oxidative stress into 12/15-lipoxygenase dependent- and AIF-mediated cell death. Cell Metab., 8, 237-248.
20. Diwadkar-Navsariwala, V. et al. (2006) Selenoprotein deficiency accelerates prostate carcinogenesis in a transgenic model. Proc. Natl Acad. Sci. USA, 103, 8179-8184.
21. Stemm, D.N. et al. (2008) Effect of dietary selenium on the promotion of hepatocarcinogenesis by 3, 3', 4, 4'-tetrachlorobiphenyl and 2, 2', 4, 4', 5, 5'-hexachlorobiphenyl. Exp. Biol. Med. (Maywood), 233, 366-376.
22. Burk, R.F. et al. (2008) Selenium deficiency activates mouse liver Nrf2-ARE but vitamin E deficiency does not. Free Radic. Biol. Med., 44, 1617-1623.
23. Suzuki, T. et al. (2008) Deletion of the selenocysteine tRNA gene in macrophages and liver results in compensatory gene induction of cytoprotective enzymes by Nrf2. J. Biol. Chem., 283, 2021-2030.
24. Slocum, S.L. et al. (2011) Nrf2: control of sensitivity to carcinogens. Arch. Toxicol., 85, 273-284.
25. Ng, L. et al. (2004) Hearing loss and retarded cochlear development in mice lacking type 2 iodothyronine deiodinase. Proc. Natl Acad. Sci. USA, 101, 3474-3479.
26. Fradejas, N. et al. (2011) Selenoprotein S expression in reactive astrocytes following brain injury. Glia, 59, 959-972.